Akebia (AKBA) Q1 2026 Earnings Transcript

Akebia reported Q1 revenue of $53.5 million, down from $57.3 million, but Vafseo net product revenue rose 32% to a record $15.8 million as patients on therapy increased 60% quarter over quarter to nearly 7,500. The offset was weaker Auryxia sales of $36.2 million, down from $43.8 million, due to lower pricing and added generic competition, which also helped push the company to a $9.1 million net loss versus $6.1 million net income a year ago. Management said cash of $162.6 million should fund operations for at least two years and highlighted ongoing pipeline progress in praliciguat, AKB-097, and AKB-9090.

Analysis

The commercial inflection is less about top-line noise and more about protocol capture. Once dialysis centers shift to observed dosing, the product stops behaving like a classic specialty launch and starts behaving like an embedded formulary workflow, which raises switching costs and should compress future volatility in refill adherence. That said, the market is likely underestimating how much of the current growth is still “easy share” from existing center conversions rather than broad end-market expansion; the real test is whether DaVita becomes a second-wave accelerant or merely a slow follow-on.

The bigger second-order effect is margin. Auryxia erosion is no longer just a revenue headwind; it is actively distorting gross margin through write-downs and inventory mismatch, which means the earnings inflection will lag the commercial story by several quarters. If Vafseo ramps but Auryxia rolls off faster than expected, investors could see a misleadingly flat or even worsening P&L in the next 1-2 quarters despite improving underlying unit economics.

The pipeline is valuable mostly as a duration extender, not near-term valuation support. Praliciguat and AKB-9090 give management a credible shot at re-rating the asset base, but these are 2027 stories and should be discounted heavily until enrollment and early efficacy data de-risk them. The most interesting contrarian angle is that the stock may deserve a higher strategic multiple if the dialysis adoption curve proves repeatable across organizations, because that creates a platform-like commercial model rather than a one-product story.

Near-term risk is binary around protocol adoption speed and whether the observed-dosing adherence rate holds as the patient base scales. If the 86% first-refill rate slips materially, the market will likely reassess the sustainability of the current uptake, especially before DaVita conversion. Conversely, a clean DaVita transition in 2H26 would be the first catalyst capable of pulling consensus forward by more than one quarter.

Key Decisions for Investors

• Go long AKBA on pullbacks over the next 2-6 weeks, but size as a catalyst trade rather than a core hold; upside comes from a DaVita protocol conversion in 2H26, while downside is limited by cash runway and visible launch momentum.
• Pair trade: long AKBA / short a dialysis-reimbursement-sensitive basket proxy (or underweight managed care exposure) to isolate Vafseo adoption from reimbursement noise; thesis works if observed dosing becomes sticky and the stock re-rates on product mix.
• Buy AKBA 6-12 month call spreads instead of common if available; the setup is a delayed upside convexity story tied to 2H26 protocol adoption and year-end VOCAL data, with Auryxia erosion capping near-term equity beta.
• Do not short AKBA outright into the quarter; the better short is on any post-rally strength if the market prices in linear Vafseo growth before DaVita actually converts, since execution risk is concentrated in one partner and one protocol change.
• Monitor for a long/short pair versus a profitable nephrology peer if one exists in the portfolio; AKBA should outperform on commercial surprise but underperform if margin deterioration from Auryxia write-downs overwhelms Vafseo revenue growth.